SLC45A2 and neoplasm: In addition, compared to MART-1 and PMEL-specific T cells, which also show a strong reactivity against HLA-A*02+ primary melanocytes along with tumor cells, SLC45A2-specific T cells target tumors cells had a reduced reactivity against HLA-A2+ primary melanocytes [33,34].